The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a registry or clinical study to monitor how well patients fare for at least two years after treatment.


Reuters: Health News … More ادامه مطلب

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Time limit is exhausted. Please reload CAPTCHA.